Ingo Hartung/X
Apr 29, 2025, 04:30
Ingo Hartung: Kevan Shokat Opens AACR25 with KRas Breakthroughs in Targeted Therapy
Ingo Hartung, Executive Director, Head of Medicinal Chemistry and Drug Design at Merck Healthcare, shared a post on X:
“Highly significant selection of the first speaker in the opening plenary at AACR25: Kevan Shokat talking about the impressive progress in targeting KRas with small molecules. Decades of investing into fundamental science now generating first clinical impact. And much more to come.”
Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared a post by Ingo Hartung, adding:
“KRAS: from undruggable to this.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 29, 2025, 04:17
Apr 29, 2025, 04:10
Apr 29, 2025, 03:29